NO20051181L - Fremgangsmate for fremstilling av en steril hoy molekylaervekts hyaluronsyreformulering - Google Patents

Fremgangsmate for fremstilling av en steril hoy molekylaervekts hyaluronsyreformulering

Info

Publication number
NO20051181L
NO20051181L NO20051181A NO20051181A NO20051181L NO 20051181 L NO20051181 L NO 20051181L NO 20051181 A NO20051181 A NO 20051181A NO 20051181 A NO20051181 A NO 20051181A NO 20051181 L NO20051181 L NO 20051181L
Authority
NO
Norway
Prior art keywords
molecular weight
high molecular
preparing
hyaluronic acid
weight hyaluronic
Prior art date
Application number
NO20051181A
Other languages
English (en)
Other versions
NO334523B1 (no
Inventor
Stefano Carlino
Original Assignee
Medidom Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31502852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051181(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medidom Lab filed Critical Medidom Lab
Publication of NO20051181L publication Critical patent/NO20051181L/no
Publication of NO334523B1 publication Critical patent/NO334523B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

En fremgangsmåte for å fremstille en steril bruksklar vandig farmasøytisk formulering som omfatter et høymolekylvekts hyaluronsyresalt (HA) ved en spesifisert konsentrasjon, omfatter trinnene: å fremskaffe en vandig formulering omfattende høymolekylvekts-HA ved en konsentrasjon som er mindre enn den spesifiserte sluttkonsentrasjon; passere nevnte vandige formulering gjennom et filter som har en porestørrelse som er mindre enn 45 føn; konsentrere nevnte vandige formulering ved å tilføre et vakuum og koke av vann inntil nevnte spesifiserte konsentrasjon blir nådd.
NO20051181A 2002-08-07 2005-03-04 Fremgangsmåte for fremstilling av en steril høy molekylærvekts hyaluronsyreformulering NO334523B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02405681 2002-08-07
PCT/IB2003/003524 WO2004014399A1 (en) 2002-08-07 2003-08-04 Process for preparing a sterile high molecular weight hyaluronic acid formulation

Publications (2)

Publication Number Publication Date
NO20051181L true NO20051181L (no) 2005-05-06
NO334523B1 NO334523B1 (no) 2014-03-31

Family

ID=31502852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051181A NO334523B1 (no) 2002-08-07 2005-03-04 Fremgangsmåte for fremstilling av en steril høy molekylærvekts hyaluronsyreformulering

Country Status (21)

Country Link
US (1) US7939655B2 (no)
EP (1) EP1526859B1 (no)
JP (1) JP4597672B2 (no)
KR (1) KR101169473B1 (no)
CN (1) CN100366296C (no)
AU (1) AU2003255892B2 (no)
BR (1) BRPI0312669B8 (no)
CA (1) CA2492739C (no)
DK (1) DK1526859T3 (no)
ES (1) ES2397382T3 (no)
HK (1) HK1080715A1 (no)
HR (1) HRP20041230B1 (no)
IL (1) IL166231A (no)
MX (1) MXPA05000533A (no)
NO (1) NO334523B1 (no)
NZ (1) NZ538019A (no)
PL (1) PL217885B1 (no)
PT (1) PT1526859E (no)
SI (1) SI1526859T1 (no)
WO (1) WO2004014399A1 (no)
ZA (1) ZA200500259B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326883C (zh) * 2005-11-04 2007-07-18 山东福瑞达生物化工有限公司 一种透明质酸钙的制备方法
CN100478360C (zh) * 2006-10-31 2009-04-15 山东福瑞达生物化工有限公司 将浓缩用于透明质酸或其盐的生产的方法
WO2009063291A1 (en) 2007-11-13 2009-05-22 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers
KR101449687B1 (ko) * 2008-03-13 2014-10-14 주식회사 바이오랜드 저분자 및 고분자 히알루론산과 유근피로부터 분리된다당체 추출물을 함유하는 노화방지용 조성물
US8283463B2 (en) * 2010-02-09 2012-10-09 Bausch & Lomb Incorporated Sterile hyaluronic acid solutions
KR101379930B1 (ko) * 2011-12-12 2014-04-14 가톨릭대학교 산학협력단 후발성 백내장 억제용 조성물 및 이의 제조 방법
CN112118849A (zh) 2018-02-06 2020-12-22 瑞珍实验室 交联透明质酸及与prp/bmc的组合
CN118512390A (zh) * 2018-09-20 2024-08-20 香港科技大学 滴眼剂组合物
WO2020057606A1 (en) * 2018-09-20 2020-03-26 The Hong Kong University Of Science And Technology Eyedrop compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US5093487A (en) * 1986-01-06 1992-03-03 Mobay Corporation Low viscosity high molecular weight filter sterilizable hyaluronic acid
JP2893451B2 (ja) * 1988-08-09 1999-05-24 昭和産業株式会社 高分子量のヒアルロン酸を製造する方法
IT1251151B (it) * 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
IT1259090B (it) 1992-04-17 1996-03-11 Fidia Spa Biomaterialli per protesi d'osso
JP2844296B2 (ja) * 1993-06-29 1999-01-06 正樹 佐久間 真空濃縮装置
CN1064372C (zh) * 1994-08-26 2001-04-11 顾其胜 透明质酸钠制剂的制备方法
KR19980080116A (ko) 1997-03-27 1998-11-25 히라따 다다시 히알루론산 나트륨의 정제법
CH692919A5 (fr) * 1999-01-28 2002-12-13 Trb Chemedica S A Procédé de purification de l'acide hyaluronique à poids moléculaire élevé.
US6660853B2 (en) * 2000-12-15 2003-12-09 Al Prescott Method for purifying high molecular weight hyaluronic acid
EP1217008B1 (en) 2000-12-19 2006-03-01 Seikagaku Corporation Photocurable hyaluronic acid derivative and process for producing the same, and photocured crosslinked hyaluronic acid derivative and medical material using the same

Also Published As

Publication number Publication date
JP2005536530A (ja) 2005-12-02
KR101169473B1 (ko) 2012-07-30
HRP20041230A2 (en) 2005-06-30
IL166231A0 (en) 2006-01-15
DK1526859T3 (da) 2013-02-04
HRP20041230B1 (hr) 2013-02-28
CN100366296C (zh) 2008-02-06
PT1526859E (pt) 2013-01-25
MXPA05000533A (es) 2005-04-19
US7939655B2 (en) 2011-05-10
IL166231A (en) 2011-10-31
CN1674920A (zh) 2005-09-28
AU2003255892B2 (en) 2008-02-21
BRPI0312669B1 (pt) 2015-08-11
EP1526859B1 (en) 2012-10-24
BR0312669A (pt) 2005-04-26
KR20050044900A (ko) 2005-05-13
NZ538019A (en) 2006-02-24
SI1526859T1 (sl) 2013-01-31
WO2004014399A1 (en) 2004-02-19
NO334523B1 (no) 2014-03-31
EP1526859A1 (en) 2005-05-04
JP4597672B2 (ja) 2010-12-15
CA2492739C (en) 2011-05-31
HK1080715A1 (en) 2006-05-04
ZA200500259B (en) 2005-12-28
PL373893A1 (en) 2005-09-19
AU2003255892A1 (en) 2004-02-25
BRPI0312669B8 (pt) 2021-05-25
US20060052336A1 (en) 2006-03-09
PL217885B1 (pl) 2014-08-29
ES2397382T3 (es) 2013-03-06
CA2492739A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
NO20051181L (no) Fremgangsmate for fremstilling av en steril hoy molekylaervekts hyaluronsyreformulering
NO20035210L (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
NO20061674L (no) Sterilisering ved hoyt trykk for avsluttende sterilisering av farmasoytiske preparater og medisinske produkter
CA2258217A1 (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
NO924873D0 (no) Fremgangsmaate for fremstilling av hyaluronsyre og fraksjonering av ren hyaluronsyre til oftalmologisk anvendelse
BR0207294A (pt) Composto, processo para a preparação de um composto ou de um sal farmaceuticamente aceitável ou um éster hidrolisável in vivo dos mesmos, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável ou um éster hidrolisável in vivo dos mesmos, e, método para a produção de um efeito inibitório do ciclo celular (antiproliferação celular) em um animal de sangue quente
NO20091168L (no) Hoyselektive reopptaksinhibitorer for norepinefrin
ATE499121T1 (de) Viskoelastische lösungen mit natriumhyaluronat und hydroxypropylmethylcellulose, herstellung und verwendungen
NO20062370L (no) Amidderivater
AU2003294879A1 (en) Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation
NO20061417L (no) Syreinneholdende oxaliplatinformuleringer
CA3156303A1 (en) 5-FLUORONICOTINAMIDE DERIVATIVES AND THEIR USES
DK1373207T3 (da) Nyt amlodipincamsylat og fremgangsmåde til fremstilling heraf
NO20050529L (no) Ciclesonidinneholdende steril vandig suspensjon
NO20055750L (no) Nye kjemiske forbindelser
NO20050247L (no) Lavmolekylaert oversulfatert polysakkarid
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
NO20075194L (no) vaksine
DK1663141T3 (da) Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin
SE0301577L (sv) Lösning med låg natriumhalt
ATE474552T1 (de) ßFESTE DOSIERUNGSFORM ZUR OKULAREN APPLIKATION EINER WIRKSUBSTANZ, LÖSLICHE, FESTE OPHTHALMISCHE EINLAGE SOWIE HERSTELLUNGSVERFAHREN DAFÜRß
RU1803110C (ru) Способ получени глазных капель
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
AU6996500A (en) Bile acid-substituted phenyl-alkenoylguanidines, method for producing said phenyl-alkenoylguanidines, use thereof as medicaments or diagnostic reagents and medicaments containing the same
PT1218401E (pt) 4-benzilaminoquinolinas conjugadas com acido biliar e seus heterociclicos metodos de sua producao medicamentos contendo estes compostos e sua aplicacao

Legal Events

Date Code Title Description
MK1K Patent expired